Consensus Design Therapeutics, Inc.

Stocks

DSGN

US25056L1035

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-30 EDT			5-day change	1st Jan Change
10.68 ^USD	-3.44%		+4.30%	+13.86%

10-02	Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target	MT
09-20	Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index	CI

Evolution of the Average Target: Design Therapeutics, Inc.

Evolution of the Target Price: Design Therapeutics, Inc.

Changes in Analyst Recommendations: Design Therapeutics, Inc.

283b8772f14746a1a98a9ce933e3da8._p7fE8Pk4n2eUuKjwd8zdLL37v5rVDSu6pe16K8wGbw.y8qxPrmcmjfwF47vtatgINC1i4YMIlPem6DsuO5yeNC1151E8o_bG80Gtw~0d343e2393dbc9610560fc3777c0a8df

Analysts' recommendations: Design Therapeutics, Inc.

10-02	Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target	MT
05-12	Cantor Fitzgerald Initiates Design Therapeutics at Overweight	MT
05-04	Oppenheimer Raises Price Target on Design Therapeutics to $21 From $18, Keeps Outperform Rating	MT
05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
03-16	Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target	MT
03-10	RBC Raises Price Target on Design Therapeutics to $14 From $13, Keeps Outperform, Speculative Risk	MT
01-07	Oppenheimer Initiates Design Therapeutics at Outperform With $18 Price Target	MT
12-03	Design Therapeutics Shares Rise After Leerink Upgrade	MT
12-03	Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7	MT
11-20	Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says	MT
11-20	RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk	MT
11-06	RBC Raises Price Target on Design Therapeutics to $6 From $5, Keeps Sector Perform, Speculative Risk	MT
25-03-11	RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk	MT
24-05-07	Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	MT
23-11-14	RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	MT
23-11-14	Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	MT
23-08-15	Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	MT
23-08-15	SVB Downgrades Design Therapeutics to Market Perform From Outperform, Cuts Price Target to $6 From $22	MT
23-08-15	Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	MT
23-08-15	RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk	MT
23-05-10	RBC Trims Price Target on Design Therapeutics to $23 From $24, Maintains Outperform Rating, Speculative Risk Qualifier	MT
23-05-10	Wedbush Trims Design Therapeutics' Price Target to $19 From $20, Keeps Outperform Rating	MT
23-05-04	Goldman Sachs Upgrades Design Therapeutics to Neutral From Sell, Price Target is $6	MT
23-03-15	Wedbush Lifts Design Therapeutics' Price Target to $20 From $19, Keeps Outperform Rating	MT
22-12-09	SVB Securities Lowers Price Target on Design Therapeutics to $22 From $30, Maintains Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DESIGN THERAPEUTICS, INC.					+103.32%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+36.32%
	Weighted average by Cap.					+27.14%